Related Experiment Video
Updated: Apr 22, 2026
09:47
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
2.0K
Cohort profile Davos Alzheimer's Collaborative DAC Egypt Cohort.
Sara A Moustafa1, Salma Mowafi1,2, Gharib Fawi3
1Institute of Global Health and Human Ecology, The American University in Cairo, Cairo, Egypt.
Npj Aging
|April 20, 2026
Summary
The new Davos Alzheimer's Collaborative (DAC) Egypt Cohort study examines cognitive aging in older Egyptians. It highlights high chronic disease rates and socioeconomic impacts on cognitive performance, informing dementia research.
Area of Science:
- Gerontology
- Neuroscience
- Public Health
Background:
- Cognitive aging and dementia risk factors are understudied in Middle Eastern populations.
- The Davos Alzheimer's Collaborative (DAC) Egypt Cohort (DAC-Egypt) addresses this gap.
- Understanding cognitive health in diverse aging populations is crucial for global health.
Purpose of the Study:
- To characterize cognitive decline trajectories in older Egyptian adults.
- To identify dementia risk factors within this specific demographic.
- To establish a foundation for early detection and intervention strategies for Alzheimer's disease and related disorders (ADRD).
Main Methods:
- Recruited 1,530 participants aged 55+ using convenience sampling.
- Collected comprehensive baseline data on demographics, health, lifestyle, and cognition.
- Utilized traditional neuropsychological tests alongside innovative digital voice, speech, and olfactory assessments.
Main Results:
- Identified a high prevalence of chronic diseases among older Egyptians.
- Observed significant socioeconomic disparities impacting cognitive performance.
- Collected blood samples and dried blood spot (DBS) cards for future biomarker and genetic research.
Conclusions:
- The DAC-Egypt cohort provides critical insights into cognitive aging in an underrepresented population.
- Findings underscore the need for culturally sensitive approaches to dementia research and care.
- This study will advance understanding of ADRD and inform targeted interventions for cognitive health.
More Related Videos
12:28Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
18.2K
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.4K
Related Concept Videos
01:29Alzheimer Disease l: Introduction
7
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
7
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
01:23Alzheimer Disease ll: Pathophysiology
7
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
7
01:21Huntington Disease l: Introduction
14
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show...
14
01:22Dementia l: Introduction
7
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
7